MKMedha Kallem

Medha Kallem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Medha Kallem has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond the Liver: Fontan-Associated Liver Disease Score as a Predictor of Adverse Cardiac Events and All-Cause Mortality

    by Mollie Westrick, Lindsey C. Ivey, Cheryl L. Raskind-Hood, Fred H. Rodriguez, Medha Kallem, Ryan Ford, Rene Romero, Ryan O. Sheets, Yuting Guo, Abeed Sarker, et al.

  • Open Access

    Mid-term outcomes of Y-graft and age-matched extracardiac and lateral tunnel Fontan patients

    by Medha Kallem, Wendy M. Book, Fred H. Rodriguez, Mollie Westrick, Lindsey C. Ivey, Cheryl L. Raskind-Hood

    Background: The bifurcated Y-graft Fontan was designed with computational fluid dynamics models that predicted reduced venous pressures, improved hepatic flow distribution, and reduced blood flow collision. Addressing these concerns was thought to improve complications associated with the traditional extracardiac and lateral tunnel techniques. However, clinical outcome data comparing the Y-graft to conventional approaches remain limited. Methods: This retrospective cohort study evaluated patients aged 0–18 years who underwent clinical evaluation after Fontan operations between 2010 and 2023. Y-graft patients were age-matched 1:2 to extracardiac and lateral tunnel cohorts. Outcomes were assessed from the first outpatient cardiology visit at least one-year post-Fontan to the last visit within the study period. The primary outcome was a composite of death, stroke, advanced heart failure referral, or cardiac intervention (including balloon angioplasty, stenting, coiling, or fenestration). Cardiac intervention alone and surgical revision alone served as secondary outcomes. Results: A total of 165 patients were analysed. Baseline demographics were similar across cohorts at the time of index encounter. The composite outcome occurred at comparable rates across groups ( p = 0.761). Cardiac intervention rates ( p = 0.873) and surgical revision rates ( p = 0.378) were similar. Conclusions: Despite the theoretical haemodynamic advantages of the Y-graft Fontan, no significant mid-term clinical benefit was observed compared with the extracardiac or lateral tunnel Fontan techniques. These findings suggest that computational fluid dynamics modelling may not fully capture the physiologic complexity of Fontan circulation, warranting reassessment of the Y-graft’s continued use and further long-term outcome analysis.

  • Open Access

    Beyond the Liver: Fontan-Associated Liver Disease Surveillance Results as a Predictor of Adverse Cardiac Events and All-Cause Mortality

    by Mollie Westrick, Lindsey C. Ivey, Cheryl L. Raskind-Hood, Fred H. Rodriguez Iii, Medha Kellam, Ryan M. Ford, Rene Romero, Ryan Sheets, Yuting Guo, Abeed Sarker, et al.

    Background: Routine surveillance for Fontan-associated liver disease (FALD), including hepatic imaging and laboratory studies, is standard care for adolescents and adults with Fontan circulation, yet the prognostic utility of these findings for predicting adverse outcomes remains unknown.Methods: We retrospectively reviewed 368 patients with Fontan circulation who underwent hepatic imaging between 2010 and 2023, linked to state death certificates. FALD severity was classified as severe (abnormal imaging with varices, ascites, or splenomegaly [VAS]), moderate (abnormal laboratory results with or without imaging abnormalities, or splenomegaly with otherwise normal imaging), or mild (normal laboratory results). Associations between surveillance findings and advanced heart failure therapy referral (AHFR) or all-cause mortality were assessed.Results: Median age at initial imaging encounter was 20.6 years; 54.6% were male, 54.1% had a systemic left ventricle, and 17.1% had heterotaxy. FALD was severe in 31.8%, moderate in 48.9%, and mild in 19.3%. AHFR and mortality increased with FALD severity: severe (17.9% AHFR, 20.5% mortality), moderate (12.2%, 10.6%), and mild (2.8%, 2.8%) (p<0.01 and p<0.001, respectively). Laboratory abnormalities were present in 76.1% of those with severe FALD and were independently associated with adverse outcomes. Ten-year overall survival was 96%, 86%, and 67%, and event-free survival was 93%, 74%, and 50%, for mild, moderate, and severe FALD, respectively.Conclusions: FALD severity, classified using routine clinical test results, effectively risk-stratifies Fontan patients for AHFR-free survival and all-cause mortality, providing a clinically accessible framework to guide management and inform timely referral for advanced therapies.

  • Associations between School-Based Vision Program Outcomes and School Characteristics in 410 Schools

    by Medha Kallem, Xinxing Guo, Xi Dai, Christina Ambrosino, Andrew Nguyen, David S. Friedman, Michael X. Repka, Nick Kourgialis, Megan Collins